IPHA

Innate Pharma

2.11 USD
+0.00
0.00%
Updated Jul 31, 3:53 PM EDT
1 day
0.00%
5 days
1.44%
1 month
15.93%
3 months
-5.38%
6 months
15.30%
Year to date
12.83%
1 year
-1.86%
5 years
-65.30%
10 years
-65.12%
 

About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Employees: 181

0
Funds holding %
of 7,324 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

11% more funds holding

Funds holding: 9 [Q4 2024] → 10 (+1) [Q1 2025]

11% more capital invested

Capital invested by funds: $255K [Q4 2024] → $282K (+$26.8K) [Q1 2025]

0.02% more ownership

Funds ownership: 0.17% [Q4 2024] → 0.19% (+0.02%) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for IPHA.

Financial journalist opinion

Neutral
Business Wire
2 days ago
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)-- #IRConference--Innate Pharma announces its participation in BTIG virtual biotechnology conference.
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
Neutral
Business Wire
1 month ago
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences.
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
Neutral
Business Wire
1 month ago
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an establish.
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
Neutral
Business Wire
2 months ago
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Neutral
Business Wire
2 months ago
Outcome of Innate Pharma's 2025 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.
Outcome of Innate Pharma's 2025 Annual General Meeting
Neutral
Business Wire
2 months ago
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncol.
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
Neutral
Business Wire
2 months ago
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. “We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical developmen.
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Neutral
Business Wire
2 months ago
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. Abstract details Antitumor characterization of IPH6501, a novel il2v-armed tetraspecifi.
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
Neutral
Seeking Alpha
2 months ago
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Sonia Quaratino - Chief Medical Officer Frederic Lombard - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Neutral
Business Wire
2 months ago
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025. “The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “Sanofi's €15 million equity investment reflects our shared conviction in the potential of ou.
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
Charts implemented using Lightweight Charts™